Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Milestone Pharmaceuticals ( (MIST) ) has issued an announcement.
Milestone Pharmaceuticals said it will release its fourth-quarter and full-year 2025 results and provide a business update on March 20, 2026, before U.S. markets open. Management will discuss the results with investors on a same-day conference call and webcast at 8:30 a.m. ET, with a replay to be posted on the company’s website.
The scheduled update gives investors another look at the commercial trajectory of CARDAMYST nasal spray and the broader cardiovascular pipeline. The event may offer clues on uptake of its approved PSVT therapy and progress in developing etripamil for AFib-RVR, both of which are key to Milestone’s growth prospects.
The most recent analyst rating on (MIST) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Milestone Pharmaceuticals stock, see the MIST Stock Forecast page.
Spark’s Take on MIST Stock
According to Spark, TipRanks’ AI Analyst, MIST is a Neutral.
The score is held down primarily by weak financial performance (no current revenue, widening losses, and significant cash burn with elevated leverage). Offsetting this, corporate events are strongly positive—FDA approval/commercial launch and non-dilutive financing materially improve the business outlook—while technical signals remain soft and valuation provides limited support due to ongoing losses.
To see Spark’s full report on MIST stock, click here.
More about Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative cardiovascular medicines for patients with specific heart conditions. Its lead product, CARDAMYST (etripamil) nasal spray, is an FDA-approved calcium channel blocker for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults and is also being developed for treating symptomatic episodic attacks associated with AFib-RVR.
Average Trading Volume: 4,175,913
Technical Sentiment Signal: Strong Sell
Current Market Cap: $145.6M
See more insights into MIST stock on TipRanks’ Stock Analysis page.